Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Say NO to Novartis!

March 19, 2012

Novartis, the Swiss-based pharmaceutical giant, continues its assault on India's generic pharmaceutical industry -- legally challenging India's patent law that allows the nation to supply nearly 80% of the developing world's access to high-quality, affordable, life-saving medications.

India's patent law effectively stops evergreening, a tactic used by pharmaceutical companies to make minor tweaks on medications to extend their stranglehold on a patent that is about to expire.

Should Novartis succeed on March 28th, a dangerous precedent will be set ...

With a chain-reaction of serious consequences.

The costs?

Crippling the generic pharmaceutical industry

Making essential medications even more cost-prohibitive

Cutting off the supply of medications used by NGO's worldwide

Millions of lives that are dependent on these drugs to fight diseases like HIV/AIDS.

Say NO to Novartis

Send the message to Novartis that no loss of human life can ever be tolerated for profits, by signing a petition here.

Learn more on how to Occupy Pharma by joining our working group.



  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by HIV Prevention Justice Alliance. Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.
 
See Also
More Calls to Action

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement